Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer

Nuclear Medicine and Biology

Volumn 36, Issue 4, 2009, Pages 363-369

  Rasaneh, Samira ^a   Rajabi, Hossein ^a   Babaei, Mohammad Hossein ^b   Daha, Fariba Johari ^b   Salouti, Mojtaba ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Breast cancer; DOTA; Herceptin; Lutetium 177; Radioimmunotherapy; Trastuzumab

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; LUTETIUM 177; PHOSPHATE BUFFERED SALINE; TRASTUZUMAB; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; BUFFER; LUTETIUM; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ISOTOPE LABELING; RADIOIMMUNOTHERAPY; THIN LAYER CHROMATOGRAPHY; BLOOD; BREAST TUMOR; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG STABILITY; METHODOLOGY; QUALITY CONTROL; STAINING; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; BUFFERS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG STABILITY; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LUTETIUM; QUALITY CONTROL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; STAINING AND LABELING;

EID: 65349187116     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.015     Document Type: Article

References (21)

1. Metro G., Mottolese M., and Fabi A. HER-2-Positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother 9 (2008) 2583-2601
2. Bange J., Zwick E., and Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 7 (2001) 548-552
3. Agrawal A., Gutteridge E., Gee J., Nicholson R., and Robertson J.R. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12 (2005) s135-s144
4. Nahta R., and Esteva F. HER-2-Targeted therapy - lessons learned and future directions. Clin Cancer Res 9 (2003) 5078-5084
5. Albanell J., Codony J., Rovira A., Mellado B., and Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532 (2003) 253-268
6. 111In-DTPA-trastuzumab. Br J Pharmacol 143 (2004) 99-106
7. Costantini D., Chan C., Cai Z., Vallis K., and Reilly R. (111)In-Labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 48 (2007) 1357-1368
8. 188Re-herceptin. Nucl Med Biol 32 (2005) 59-65
9. Nayak D., and Lahiri S. Application of radioisotopes in the field of nuclear medicine. J Radioanal Nucl Chem 42 (1999) 423-432
10. 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 34 (2007) 173-183
11. 90Y labeled DOTA analogues conjugated to B72.3. Nucl Med Biol 34 (2007) 493-502
12. Lewis M., Kao J., Anderson A., Shively J., and Raubitschek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjug Chem 12 (2001) 320-324
13. Lindmo T., Boven E., Cuttitta F., Fedorko J., and Bunn P.J. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72 (1984) 77-89
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
15. Ménard S., Pupa S., Campiglio M., and Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 22 (2003) 6570-6578
16. Tan A., and Swain S. Ongoing adjuvant trials with trastuzumab in breast cancer. Semi Oncol 30 (2003) 54-64
17. Seidman A., Hudis C., Pierri M., Shak S., Paton V., Ashby M., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002) 1215-1221
18. Fleck L. The costs of caring: Who pays? Who profits? Who panders?. Hastings Cent Rep 36 (2006) 13-17
19. 177Lu?. J Nucl Med 46 (2005) 634-641
20. 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 46 (2005) 850-858
21. Borchardt P., Yuan R., Miederer M., McDevitt M., and Scheinberg D. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 63 (2003) 5084-5090